Z Forms A Phenoxy Alkyl Or Phenoxy Alkenyl Radical Patents (Class 514/543)
  • Patent number: 9539232
    Abstract: Disclosed is the therapeutic potential of Calebin A for osteoporosis (bone loss) caused by aging or chronic disease conditions like cancer. Calebin A is shown to down modulate osteoclastogenesis induced by receptor activator of nuclear factor (NF)-?B ligand (RANKL) signalling thereby having therapeutic potential for osteoporosis.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 10, 2017
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 9399631
    Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 26, 2016
    Assignees: UNIVERSITY OF SOUTH FLORIDA, MCGILL UNIVERSITY, THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
  • Patent number: 9220703
    Abstract: The novel therapeutic potential of Calebin A and compositions thereof to prevent pathological damage to mammalian articular cartilage is disclosed.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: December 29, 2015
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
  • Patent number: 9216942
    Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: December 22, 2015
    Assignees: BAGI RESEARCH LIMITED, VERSITECH LIMITED
    Inventors: Allan Sik Yin Lau, Lai Hung Cindy Yang, Stanley Chi Chung Chik
  • Patent number: 9180110
    Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: November 10, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Ramakant Kashinath Gundu, Narayanan Murali, Girish Kumar Jain
  • Publication number: 20150119458
    Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hua Bai, Jian Hong, Lifeng Cai, Hegeng Wei, Xiaoyu Liu, Xiaohe Zheng
  • Patent number: 8933121
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: January 13, 2015
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Anjali Pandey
  • Publication number: 20140377342
    Abstract: The objective of this invention is to develop a novel wafer and capsule formulations using fenofibrate which is difficult to dissolve and control its release rate in vitro.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 25, 2014
    Inventor: Michael Li
  • Publication number: 20140364497
    Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Applicant: WOCKHARDT RESEARCH CENTRE
    Inventors: Ramakant Kashinath GUNDU, Narayanan Murali, Girish Kumar Jain
  • Patent number: 8852635
    Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: February 23, 2008
    Date of Patent: October 7, 2014
    Assignee: Wockhardt Ltd
    Inventors: Ramakant Kashinath Gundu, Narayanan Murali, Girish Kumar Jain
  • Publication number: 20140296336
    Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 2, 2014
    Applicant: ABBOTT GMBH & CO. KG
    Inventors: Gunther Berndl, Juergen Weis, Dietrich Granzow, Bernd Liepold, Ute Lander, Ulrich Westedt
  • Publication number: 20140271845
    Abstract: Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Cerovene, Inc.
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • Publication number: 20140255479
    Abstract: The present invention provides pharmaceutical compositions suitable for oral and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Inventors: Stephen M. Carl, John Stanley Vrettos, William Stern
  • Publication number: 20140255450
    Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.
    Type: Application
    Filed: February 18, 2013
    Publication date: September 11, 2014
    Applicants: VERSITECH LIMITED, PURAPHARM COMPANY LIMITED
    Inventors: ALLAN SY LAU, LAI HUNG CINDY YANG, CHI CHUNG STANLEY CHIK, CHUN BONG JAMES LI
  • Publication number: 20140255480
    Abstract: The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.
    Type: Application
    Filed: April 7, 2014
    Publication date: September 11, 2014
    Applicant: ETHYPHARM
    Inventors: Catherine HERRY, Pascal OURY
  • Publication number: 20140243378
    Abstract: Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating muscle disease and improving muscle function are also described.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Applicants: Tufts Medical Center, Inc., Children's Medical Center Corporation
    Inventors: Isabelle Draper, Louis M. Kunkel, Matthew S. Alexander, Alan S. Kopin
  • Publication number: 20140206674
    Abstract: The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Markus ZWICKL
  • Patent number: 8778401
    Abstract: The present invention encompasses formulations and methods for producing solid dispersions comprising mesoporous materials with poorly aqueous soluble active ingredients. The active ingredient is formed in the amorphous state and entrapped in the nanosized pores of the mesoporous excipients using a co-spray drying process. The pore walls of mesoporous channels stabilize the amorphous form of active ingredient against re-crystallization. The amorphous active ingredient entrapped in mesoporous channels exhibits good stability during extended storage under stress test conditions and possesses significantly enhanced dissolution rates.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: July 15, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Shou-Cang Shen, Wai Kiong Ng, Leonard Chia
  • Patent number: 8778364
    Abstract: A nanodispersion containing nanoparticles having a mean size less than 300 nm dispersed in a vehicle that includes a water miscible solvent and water. The nanoparticles contain one or more drugs, a polymer and a surfactant, and the surfactant includes a mixture of fatty acids or its salts and sterol or its derivatives or its salts.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: July 15, 2014
    Assignee: Sun Pharma Advanced Research Company Ltd.
    Inventors: Ajay Jaysingh Khopade, Natarajan Arulsudar, Subhas Balaram Bhowmick
  • Patent number: 8772290
    Abstract: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of cells under hypoxic conditions, so that it can be used for preventing or treating of diseases such as cancer, arthritis, psoriasis, diabetic retinopathy and macular degeneration.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: July 8, 2014
    Assignee: Oscotech Inc.
    Inventors: Se-Won Kim, Jung Ho Kim, Se-Nyum Kim, Dae-Pil Kang, Youn Ho Han, Guo Fan Jin, Dong-Sik Jung, Sung-Ho Park, Ji Min Kim, Jhi Zheng
  • Publication number: 20140187617
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Publication number: 20140171441
    Abstract: Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: BEND RESEARCH, INC.
    Inventors: Walter C. Babcock, Dwayne T. Friesen, Warren K. Miller, Daniel T. Smithey
  • Patent number: 8754125
    Abstract: The invention provides intravenous formulations of propofol in an oil-in-water emulsion, having a combination of preservatives.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: June 17, 2014
    Assignee: The Medicines Company
    Inventors: Min Ding, Rajeshwar Motheram, Glenn Sblendorio
  • Publication number: 20140162988
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: June 12, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Publication number: 20140162987
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: June 12, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Publication number: 20140161881
    Abstract: The present invention provides a reduced dose oral pharmaceutical composition comprising mixture of nanoparticulate fenofibrate and micronized fenofibrate and one or more pharmaceutically acceptable excipients.
    Type: Application
    Filed: April 1, 2013
    Publication date: June 12, 2014
    Applicant: Lupin Atlantis Holdings, S.A.
    Inventors: Venkat Reddy KALLEM, Raghu Rami Reddy KASU, Subhasis DAS, Vijaya Kumar THOMMANDRU
  • Patent number: 8747875
    Abstract: An insecticidal composition comprising stabilized pyrethrins or pyrethroids is provided. Such composition includes stabilizing effective amount of N,N-dialkyl fatty acid amide solvents and certain ultraviolet-light absorbers. In such composition, the pyrethrins or pyrethroid can retain their insecticidal activity for an acceptably long period of time. Therefore, an advantage of this invention is to provide a topical pyrethrins or pyrethroid based insecticide which can remain effective in light over a long time period. Another advantage of this invention is to provide a stabilized topical pyrethrins or pyrethroid insecticide insecticidal formulation containing a high concentration of the active pyrethrins or pyrethroid ingredient to minimize the volume of formulation required.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: June 10, 2014
    Assignee: The Hartz Mountain Corporation
    Inventors: W. Lance H. Hemsarth, Linda Valencia
  • Publication number: 20140134256
    Abstract: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Inventors: E. Itzhak LERNER, Vered ROSENBERGER, Moshe FLASHNER-BARAK, Anna DRABKIN, Naomi MOLDAVSKI
  • Publication number: 20140128353
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: Biocopea Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 8653238
    Abstract: Conjugates of a cargo molecule with a transporter molecule are disclosed, where the cargo molecule and the transporter molecule are linked covalently by a releasable linker. The cargo of the conjugate can be a biologically active agent or a reporter molecule. The transporter modulates the transport of the cargo across a biological barrier (e.g., a cell membrane) compared to the transport of the unconjugated cargo. Releasable linkers suitable for rapid and facile conjugation to various types of cargo and transporters are also disclosed, along with methods for using the linkers in the synthesis of conjugates.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: February 18, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Paul A. Wender, Elena A. Goun, Lisa R. Jones
  • Publication number: 20140038931
    Abstract: The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.
    Type: Application
    Filed: August 27, 2013
    Publication date: February 6, 2014
    Applicant: ACTIVUS PHARMA CO., LTD.
    Inventors: Takashi HIROKAWA, Takahiro TADA, Jun NIHIRA
  • Patent number: 8642532
    Abstract: This invention is a method of using a class of excipients for protein formulation to reduce and/or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated. This method has never been disclosed anywhere in the literature.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: February 4, 2014
    Inventor: Guohan Yang
  • Publication number: 20130338160
    Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 19, 2013
    Inventors: Charles SHIH, Qian Shi, Hui-kang Wang
  • Publication number: 20130323304
    Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.
    Type: Application
    Filed: August 1, 2013
    Publication date: December 5, 2013
    Applicant: Banner Pharmacaps, Inc.
    Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
  • Patent number: 8592621
    Abstract: A description is given of precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease, in particular for the prevention or treatment of Type 2 diabetes. A description is also given of uses of these precursor compounds and edible compositions, preparations for nutrition or pleasure or semi-finished products and pharmaceutical preparations, containing such precursor compounds.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: November 26, 2013
    Assignee: Symrise AG
    Inventors: Jakob Peter Ley, Michael Backes, Tobias Vössing, Frauke Stähler, Wolfgang Meyerhof, Christian Wintermeyer
  • Publication number: 20130303612
    Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in a non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
    Type: Application
    Filed: February 25, 2013
    Publication date: November 14, 2013
    Applicant: Veloxis Pharmaceuticals A/S
    Inventors: Per Holm, Tomas Norling
  • Patent number: 8580775
    Abstract: The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: November 12, 2013
    Assignee: Cognis IP Management GmbH
    Inventors: Thomas Markert, Philippe Moussou, Louis Danoux, Andreas Rathjens
  • Publication number: 20130295190
    Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Applicant: New Jersey Institute of Technology
    Inventors: Ecevit Bilgili, Rajesh Dave, Anagha Bhakay, Mohammad Azad
  • Patent number: 8575215
    Abstract: A method of treating a neurodegenerative or cardiovascular disorder with a compound of the following formula: in which X, Y, A1, A2, R1, and R2 are defined herein.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: November 5, 2013
    Inventors: Yangsheng Du, Martin R. Farlow, Ruyu Du
  • Patent number: 8563607
    Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: October 22, 2013
    Assignees: University of South Florida, McGill University, The Hong Kong Polytechnic University
    Inventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
  • Publication number: 20130274297
    Abstract: The invention provides a composite of drug, polymeric carrier and at least one not cross linked polymer useful to improve the solubility of poorly water soluble drugs. The present invention comprises manufacturing process of this composite material. The manufacturing process is carried out by the solvent induced activation process, wherein the not cross-linked polymer is loaded into the composite from organic solution, possibly together with the drug. Pharmaceutical compositions comprising said composite in combination with pharmaceutical acceptable excipients are also described herein.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 17, 2013
    Applicant: APTALIS PHARMA LIMITED
    Inventors: Paolo Gatti, Italo Colombo, Dario Gervasoni, Vincenza Pironti, Lia Alborghetti, Flavio Fabiani, Luigi Boltri
  • Publication number: 20130252818
    Abstract: An amorphous formulation of a herbicidal or pesticidal substance includes a composition of the formula [A]x[MpClq]y, the composition being an ionic liquid with a melting temperature below 150° C., wherein [MpClq] is a metal chloride, x is 1, 2, 3, or 4, p is 1, 2, 3, or 4, q is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and y is 1 or 2, wherein each A is a cation that is a herbicidal or pesticidal substance or a cation precursor that is a herbicidal or pesticidal substance.
    Type: Application
    Filed: March 25, 2013
    Publication date: September 26, 2013
    Inventors: Katherine Lovejoy, Rico Del Sesto, Andrew Koppisch
  • Patent number: 8541400
    Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: September 24, 2013
    Assignee: Camurus AB
    Inventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg
  • Patent number: 8524748
    Abstract: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: September 3, 2013
    Assignee: Panmira Pharmaceuticals, LLC
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Jeannie M. Arruda, Jeffrey Roger Roppe
  • Publication number: 20130210883
    Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Inventors: Johannes Grillari, Rolf Breinbauer, Martina Schweiger, Matthias Romauch, Robert Zimmermann, Nicole Mayer, Elisabeth Schraml, Klaus Fortschegger, Regina Grillari
  • Publication number: 20130202657
    Abstract: The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02.
    Type: Application
    Filed: May 20, 2011
    Publication date: August 8, 2013
    Applicants: BASF SE, President and Fellows of Harvard College
    Inventors: Kosta Ladavac, Rodrigo E. Guerra, David Kaz, Vinothan Manoharan, Jens B. Rieger, Roland S. Koltzenburg, David A. Weitz
  • Patent number: 8501759
    Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive sleep apnea syndrome.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: August 6, 2013
    Assignee: Fournier Laboratories Ireland Limited
    Inventor: Eric Bruckert
  • Publication number: 20130156708
    Abstract: The invention relates to the use of (i) a compound of formula (I) or a (pharmaceutically) acceptable salt thereof or (ii) a mixture comprising one or more or consisting of two or more compounds of formula (I) and/or said salts wherein R1 denotes a radical in ortho-, meta, or para-position to the phenolic OH group, the radical being selected from the group consisting of E/Z-3-methylbut-1-en-1-yl, 3-methylbut-2-en-1-yl and 3-methylbut-3-en-1-yl and R2 denotes a radical in ortho-, meta, or para-position to the phenolic OH group, the radical being selected from the group consisting of H and alkyl groups with 1 to 3 C atoms as antimicrobial agent for inactivation of microorganisms, in particular for rapid inactivation of microorganisms, with the proviso that the use is not within a method for treatment of the human or animal body by surgery or therapy or within a diagnostic method practised on the human or animal body.
    Type: Application
    Filed: October 25, 2012
    Publication date: June 20, 2013
    Applicant: Symrise AG
    Inventor: Symrise AG
  • Patent number: 8444955
    Abstract: The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: May 21, 2013
    Assignee: GE Healthcare Limited
    Inventors: Alan Cuthbertson, Magne Solbakken, Dag Erlend Olberg
  • Publication number: 20130115246
    Abstract: The invention relates to reduced dose oral pharmaceutical composition of fenofibrate which exhibits substantial bioequivalence to Antara® Capsules under fasting condition and also capable of reducing the food effect on bioavailability of fenofibrate. Provided is a pharmaceutical composition comprising about 90 mg of fenofibrate particles having a D90 particle size of less than about 600 nm and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is a solid dosage form suitable for oral administration and is substantially free of food effect such that when administered orally to a human provides an AUC0-t value for fenofibric acid in the blood plasma of the human under a fed state which is higher than the AUC0-t value under a fasted state by up to 12%, wherein t is 96 hours from the administration of the pharmaceutical composition.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 9, 2013
    Applicant: Lupin Atlantis Holdings, S.A.
    Inventors: Venkat Reddy KALLEM, Raghu Rami Reddy KASU, Subhasis DAS, Vijaya Kumar THOMMANDRU, Ninad DESHPANDAY